BridgeBio Oncology Therapeutics, Inc. 10-Q filing
Filed 2026-05-12 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001193125-26-219829
- Form type
- 10-Q
- CIK
- 0001869105
- Primary document
- https://www.sec.gov/Archives/edgar/data/1869105/000119312526219829/bbot-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for BridgeBio Oncology Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-46.2M | - | - |
| Net Income | $-42.1M | - | - |
| Eps Basic | -526.11 | - | - |
| Eps Diluted | -526.11 | - | - |
| Cash And Equivalents | $52.7M | - | - |
| Total Assets | $417.6M | - | - |
| Total Liabilities | $45.4M | - | - |
| Shareholders Equity | $372.3M | - | - |
| Operating Cash Flow | $-35.9M | - | - |
| Capital Expenditures | $24,000 | - | - |